SOPHiA GENETICS Announces Instituto Mário Penna as New Customer

Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine and is a leader in the field [5] - The company has developed the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to provide actionable insights for hospitals, laboratories, and biopharma institutions globally [5] Industry Context - Cancer is the second most common cause of death in Brazil, with an estimated 704,000 new cancer cases expected between 2023 and 2025 [2] - Blood cancers rank as the fifth most common type of cancer worldwide [2] - Instituto Mário Penna, a major oncology service provider in Brazil, has implemented the SOPHiA DDM™ Platform to enhance its testing capabilities and improve data-driven treatment plans for blood-related cancers [2][3] Technological Advancements - The SOPHiA DDM™ Platform utilizes next-generation sequencing (NGS) to identify key variants from various sample types, facilitating rapid and accurate detection of disease-associated variants [3] - The platform is designed to compute a wide array of genomic variants and continuously improves its machine learning algorithms for better detection of rare and challenging cases [4] - Results from the SOPHiA DDM™ Platform are nearly 100 percent reproducible, ensuring consistent and reliable sequencing data [4]